Horizon Pharma plc (HZNP): The stock had negative money flow to the tune of ($3.74 million) on Thursday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $12.03 million, whereas, the outflow of money on downticks was $15.77 million and the ratio between the two was 0.76. The block trade had a negative net money flow of ($4.13 million). The total block trade value undertaken on upticks was $1.05 million. On the other hand, downticks amounted to $5.18 million of the traded value, which shows distribution in the stock by traders. The ratio between uptick and downtick was 0.2. Horizon Pharma plc (HZNP) closed with marginal gains of 68 cents to end the day at $18.19, an increase of 3.88% over the previous days close. The stock recorded 8.15% for the week.
Horizon Pharma plc (HZNP) stock is expected to deviate a maximum of $8.46 from the average target price of $32.29 for the short term period. 7 Street Experts have initiated coverage on the stock with the most promising target being $45 and the most muted being $24. The stock has recorded a 20-day Moving Average of 6.88% and the 50-Day Moving Average is 12.23%.
Horizon Pharma plc (NASDAQ:HZNP): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $17.87 and $17.67 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.21. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.19, notching a gain of 3.88% for the day. The total traded volume was 4,162,047 . The stock had closed at $17.51 on the previous day.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.